Table 1 Clinicopathological characteristics of study cohort
|  | Total, n = 39 | EEC, n = 25 | NEEC, n = 14 | p |
|---|---|---|---|---|
Age (years)a | 68 (50–88) | 68 (50–85) | 74,5 (54–82) | 0.098 |
BMI (kg/m2)a | 26.9 (20–51) | 27.5 (20–51) | 25.7 (22–37) | 0.289 |
Follow-up (months)a | 34 (1–168) | 34 (1–88) | 30 (2–168) | 0.946 |
Hypertensionb | Â | Â | Â | 0.133 |
 Yes | 17 | 9 (36%) | 8 (62%) | |
 No | 21 | 16 (64%) | 5 (38%) | |
Diabetes mellitusb | Â | Â | Â | 0.825 |
 Yes | 8 (21%) | 5 (20%) | 3 (23%) | |
 No | 30 (79%) | 20 (80%) | 10 (77%) | |
Tumor grade | ||||
 1 | 4 (10%) | 4 (16%) |  |  |
 2 | 16 (41%) | 16 (64%) |  |  |
 3 | 19 (48%) | 5 (20%) | 14 (100%) |  |
Histology | ||||
 Endometrioid | 25 (64%) | 25 (64%) |  |  |
 Non-endometrioid | 14 (36%) |  | 14 (36%) |  |
 Serous | 2 (5%) |  | 2 (5%) |  |
 Clear cell | 2 (5%) |  | 2 (5%) |  |
 Mixed | 5 (13%) |  | 5 (13%) |  |
 Carcinosarcoma | 5 (13%) |  | 5 (13%) |  |
FIGO stage | Â | Â | Â | 0.009* |
 Early (I-II) | 22 (56%) | 18 (72%) | 4 (29%) | |
 Advanced (III-IV) | 17 (44%) | 7 (28%) | 10 (71%) | |
Recurrencec | Â | Â | Â | 0.041* |
 Yes | 13 (33%) | 6 (24%) | 7 (58%) | |
 No | 24 (62%) | 19 (76%) | 5 (42%) | |
EC related death | Â | Â | Â | 0.542 |
 Yes | 9 (23%) | 5 (20%) | 4 (29%) | |
 No | 30 (77%) | 20 (80%) | 10 (71%) | |